Abstract
The median preoptic nucleus (MnPO) is an integrative site involved in body fluid homeostasis, cardiovascular control, thermoregulation, and sleep homeostasis. Angiotensin II (ANG II), a neuropeptide shown to have excitatory effects on MnPO neurons, is of particular interest with regard to its role in body fluid homeostasis and cardiovascular control. The present study investigated the role of angiotensin type 1a (AT1a) receptor activation on neuronal excitability in the MnPO. Male Sprague-Dawley rats were infused with an adeno-associated virus with an shRNA against the AT1a receptor or a scrambled control. In vitro loose-patch voltage-clamp recordings of spontaneous action potential activity were made from labeled MnPO neurons in response to brief focal application of ANG II or the GABAA receptor agonist muscimol. Additionally, tissue punches from MnPO were taken to asses mRNA and protein expression. AT1a receptor knockdown neurons were insensitive to ANG II and showed a marked reduction in GABAA-mediated inhibition. The reduction in GABAA-mediated inhibition was not associated with reductions in mRNA or protein expression of GABAA β-subunits. Knockdown of the AT1a receptor was associated with a reduction in the potassium-chloride cotransporter KCC2 mRNA as well as a reduction in pS940 KCC2 protein. The impaired GABAA-mediated inhibition in AT1a knockdown neurons was recovered by bath application of phospholipase C and protein kinase C activators. The following study indicates that AT1a receptor activation mediates the excitability of MnPO neurons, in part, through the regulation of KCC2. The regulation of KCC2 influences the intracellular [Cl−] and the subsequent efficacy of GABAA-mediated currents.
Keywords: angiotensin, KCC2, median preoptic nucleus, shRNA
INTRODUCTION
The median preoptic nucleus (MnPO) is located between two circumventricular organs, the subfornical organ (SFO) and the organum vasculosum of the lamina terminalis (OVLT), on the anterior wall of the third ventricle (30). It is involved in body fluid balance, central cardiovascular control, thermoregulation, and sleep homeostasis (4, 18, 30). The MnPO receives projections from the brain stem as well as from circumventricular organs and, on the basis of its neuroanatomy, is described as an integrative region (30). Projections from the circumventricular organs are traditionally thought to be especially important to the role of the MnPO in body fluid homeostasis and cardiovascular regulation (4, 30). It has been proposed that angiotensin II (ANG II) may act as a hormone at circumventricular organs and as a neurotransmitter in the central nervous system (14) although the existence of a brain renin angiotensin system has recently been challenged (40).
Functional studies suggest a role for angiotensin in the SFO-to-MnPO pathway. Activation of the SFO by direct injection of ANG II produces water intake that is blocked by the administration of the angiotensin antagonist, saralasin, in the MnPO (37). Similarly, electrical stimulation of the SFO produced excitation or inhibition of MnPO neurons, and the excitatory responses were blocked by iontophoresis of saralasin (38).
In vitro electrophysiological studies of MnPO neurons have shown that ANG II can produce a depolarization while reducing afterhyperpolarization and spike frequency adaptation (1). In a minority of MnPO cells, angiotensin decreases a leak potassium conductance and induces low-threshold calcium spikes, leading to rhythmic bursting (36). In vitro, electrical stimulation of the SFO produces rapid excitation and inhibition that are mediated by glutamate and γ-aminobutyric acid (GABA), respectively (24). Although they did not observe angiotensin-mediated responses resulting from SFO stimulation, the authors suggested that the peptide may produce delayed effects on MnPO neurons that were not readily apparent in their preparation (24). Recent studies suggest that endogenous angiotensin appears to be required to support the inhibitory effects of GABA on MnPO neurons (16). Inhibition of the AT1a receptors with either saralasin or losartan was associated with a significant decrease in inhibitory currents, whereas exogenous angiotensin increased the amplitudes of muscimol currents. Although the mechanism underlying this relationship between angiotensin and GABA has not been determined, these observations are consistent with recent reports suggesting that G protein-coupled receptors (GPCRs) can regulate the activity of the chloride cotransporter KCC2 through S940 phosphorylation (29). Activity of the angiotensin type 1a (AT1a) receptor could help stabilize KCC2 expression in the cell membrane, supporting a low intracellular chloride concentration and the inhibitory effects of GABA. In the present study, we tested the relationship between AT1a receptors and GABA-mediated inhibition in the MnPO using a virally mediated knockdown (KD) approach.
MATERIALS AND METHODS
Animals.
Experiments were performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the University of North Texas Health Science Center Institutional Animal Care and Use Committee. These experiments used 6-wk-old (250–300 g) adult male Sprague-Dawley rats (Charles River Laboratory, Wilmington, MA). Rats were individually housed in temperature-controlled rooms with a 12-h:12-h light/dark cycle with the light phase lasting from 7 AM to 7 PM. Surgeries were performed using aseptic technique, and postoperative infection was prevented by subcutaneous administration of procaine penicillin G (30,000 U). A nonsteroidal anti-inflammatory drug, carprofen (Bio-Serv, Flemington, NJ; 2 mg tablet po), was given before and after surgery for pain management.
Viral vectors and injections.
Viral vectors used in these experiments were purchased from GENEDETECT (Auckland, New Zealand). The adeno-associated viruses (AAV) (rAAV1/2) contained either a small hairpin RNA sequence targeted to the AT1a receptor (AT1a KD, GD1009-RV Rat AT1aR RNAi) or a scrambled (Scr, rAAV1/2-U6-SCR.shRNA-terminator-CAG-EGFP-WPRE-BGH-polyA) sequence. Viruses were used undiluted at a titer of 1.1 × 1012 genomic particles/ml. Both viruses expressed green fluorescent protein (GFP) to allow identification of transfected neurons.
Microinjections.
Rats were anesthetized with 2% isoflurane, and their scalps were shaved and disinfected with alcohol and iodine. Each rat was placed in a stereotaxic head frame (David Kopf, Tujunga, CA). To ensure accurate injections, skulls were leveled at two cranial suture landmarks bregma and lambda. The injector was angled 8° from medial to lateral, and the injection coordinates used for the MnPO were 0 mm anterior, 0.9 mm lateral, and 6.7 mm ventral from bregma (33). After a burr hole was drilled at the site of injection, a 30-gauge steel injector was lowered to the MnPO, and 200–300 nl of AAV was delivered at a rate of 200 nl/min. The injector was connected to a Hamilton 5-µl syringe (no. 84851; Hamilton, Reno, NV) by calibrated polyethylene tubing that was used to determine the injection volume. The injector remained in place for 5 min to allow for absorption and then was slowly withdrawn. Gel foam was packed in to the opening in the cranium. Absorbable antibiotic suture was used to close the incision site and minimize postsurgical infection.
Slice preparation.
Two weeks after the microinjection, rats were anesthetized with isoflurane (2%) and decapitated. Coronal slices (300 µm) containing the MnPO were cut using a Microslicer DTK Zero 1 (Ted Pella, Redding, CA) in ice-cold (0–1°C), oxygenated (95% O2-5% CO2) cutting solution consisting of the following (in mM): 3.00 KCl, 1.00 MgCl2·6H2O, 2.00 CaCl2, 2.00 MgSO4, 1.25 NaH2PO4, 26.00 NaHCO3, 10.00 d-glucose, and 206.00 sucrose (300 mosM, pH 7.4). Slices were incubated at room temperature in oxygenated (95% O2-5% CO2) artificial cerebrospinal fluid (aCSF) containing the following (in mM): 126.00 NaCl, 3.00 KCl, 2.00 CaCl2, 2.00 MgSO4, 1.25 NaH2PO4, 26.00 NaHCO3, and 10.00 d-glucose (300 mosM, pH 7.4) for a minimum of 1 h before recording.
Electrophysiology.
Slices containing the MnPO were transferred to a submersion recording chamber, where they were superfused with aCSF (31 ± 1°C). Slices were visualized using an upright epifluorescent microscope (BX50WI; Olympus, Waltham, MA) with differential interference contrast optics. Loose-patch voltage-clamp recordings were obtained using borosilicate glass micropipettes (1–3 MΩ) containing aCSF as the internal solution. Action potentials were amplified and digitized using Multiclamp 200B and Digidata 1440A, respectively (Molecular Devices, San Jose, CA). Signals were filtered at 2 kHz and digitized at 10 kHz. Recordings from MnPO neurons were made by targeting enhanced GFP-expressing neurons in slices prepared from rats injected with the shRNA against AT1a or the scrambled control construct (Fig. 1A).
Fig. 1.
Angiotensin 1a receptor knockdown (AT1a KD). A: digital image of green fluorescent protein (GFP) fluorescence and recording electrode from slice containing the median preoptic nucleus (MnPO) (scale bar = 20 µm). Loose-patch voltage-clamp recordings were made from GFP-positive MnPO neurons. B: results from qRT-PCR studies showing that AT1a KD (n = 7) reduced AT1a mRNA expression compared with uninjected controls (n = 6) and scrambled sequence (Scr)-injected rats (n = 7). **P < 0.01.
Baseline action potential firing was recorded for 5 min. Drugs were then focally applied for 30 s (10 psi) using a Pico spritzer (WPI, Sarasota, FL) with a patch pipette containing the drug placed 150–200 μm upstream of the recording electrode followed by an additional 10 min of recording. In some cases, the AT1a antagonist losartan was bath applied followed by focal application of ANG II (100 nM). In these instances, bath application of losartan occurred before baseline recordings and was maintained throughout the recording procedure. Compounds used were the AT1a agonist ANG II (Sigma-Aldrich, St. Louis, MO), the AT1a antagonist losartan (10 µM; Tocris, Bristol, UK), the GABAA agonist muscimol (100 µM; Sigma-Aldrich), and the GABAA antagonist bicuculline methobromide (10 µM; Sigma-Aldrich). ANG II, losartan, and bicuculline were dissolved in aCSF. Stock solutions of muscimol (100 mM) were first dissolved in 0.05 M HCl then diluted to a final concentration in aCSF (100 µM). The KCC2 blocker VU 0240511, the PKC activator phorbol 12,13-dibutyrate (PDBu), and the PLC activator m-3M3FBS were purchased from Tocris and were first dissolved in DMSO (Sigma-Aldrich) then diluted to a final concentration of 10 µM (< 0.1% DMSO) in aCSF for bath application. Parameter measured for action potential firing was spike count separated into 30-s bins.
qRT-PCR.
Punches containing the MnPO (2–3 per rat) were collected in PARIS Kit (Invitrogen, Carlsbad, CA) buffer, and RNA was purified according to manufacturer instructions. The purified RNA underwent amplification using the epicenter TargetAmp 2-Round AminoallylaRNA Amplification Kit 1.0 and purified using the RNeasy MinElute Cleanup Kit (Madison, WI). Quality and purity of the RNA were verified spectrophotemetrically on a Nanodrop 2000c (ThermoScientific, Wilmington, DE). RNA was used in the experiment when the 260- to 280-nm wavelength absorbance ratio was above 1.8. Forty nanograms of the resulting purified RNA were used for reverse transcriptase PCR via the Sensiscript Reverse Transcription Kit as previously described (7, 11, 31, 32, 34).
The cDNA that was produced from reverse transcription was used for quantitative PCR. Individual qPCR reactions consisting of 1.8 µl of cDNA, 1.2 µl of a primer mix, 7.5 µl of iQ SYBR Green Supermix, and 4.5 μl RNase-free water were performed in a 96-well plate. A Bio-Rad iQTM5 iCycler 191 system (Bio-Rad Laboratories, Hercules, CA) and thermocycler were used to perform the qPCR. Each reaction was performed in duplicate, and relative fluorescence unit data from the iCycler were analyzed according to the 2-∆∆Ct method in accordance with our previous publications (7, 11, 31, 32). Specific primer sequences are shown in Table 1.
Table 1.
Forward and reverse primer sequences used in qRT-PCR experiments
Sequence | |
---|---|
AT1a | |
Forward | 5′-AGCCTGCGTCTTGTTTTGAG-3′ |
Reverse | 5′-GCTGCCCTGGCTTCTGTC-3′ |
GABAA-β1 | |
Forward | 5′-CGTGTTCCTGGCTCTACTGG-3′ |
Reverse | 5′-TCAGTGGTTTGCGGTACTGG-3′ |
GABAA-β2 | |
Forward | 5′-GGACAATCGAGTGGCAGACC-3′ |
Reverse | 5′-GTGGATACCGCCTTAGGTCC-3′ |
GABAA-β2 | |
Forward | 5′-ATGGAACAGTGCTGTACGGG-3′ |
Reverse | 5′-ACCTGTGGCGAAGACAACAT-3′ |
KCC2 | |
Forward | 5′-CCATGGCTTTGATGTCTGTGCCAA-3′ |
Reverse | 5′-ACTCATCACAGGTGGCATTGAGGA-3′ |
S18 | |
Forward | 5′-CAGAAGGACGTGAAGGATGG-3′ |
Reverse | 5′-CAGTGGTCTTGGTGTGCTGA-3′ |
AT1a, angiotensin type 1a; GABA, γ-aminobutyric acid.
Western Blot.
Two weeks after microinjection of the AAV vectors, rats were deeply anesthetized with 2% isoflurane and then decapitated. Brains were removed and cut into 1-mm coronal sections using a commercially available brain matrix. Punches containing the MnPO (2–3 per rat) were collected in a RIPA lysis buffer containing DTT, chelators, and protease inhibitors using a blunt-tip 23-gauge needle and stored at −80°C until protein isolation and Western blots were performed. Total lysate (20–25 µg) was separated via electrophoresis on 15% acrylamide SDS gel (no. 465–1084; Bio-Rad) in Tris-glycine buffer at 100 V for 1–2 h. Samples were then transferred to a PVDF membrane (Immobilon-P; EMD-Millipore, Billerica, MA) in Tris-glycine buffer (25.0 mM Tris, 192.0 mM glycine, 0.1% SDS; pH 8.3) containing 20% methanol (vol/vol) at 50 V for 2 h at 4°C. Membranes were blocked with 5% BSA in Tris-buffered solution with Tween 20 (TBST) (25 nM Tris base, 125 mM NaCl, 0.1% Tween 20) for 30 min at room temperature. Blots were incubated in primary antibodies for Ser940 pKCC2 (1:500 rabbit polyclonal; 612-401-E15; Rockland Immunochemicals, Limerick, PA), KCC2 (1:300 rabbit polyclonal; 07-432; Millipore Sigma, Burlington, MA), GABAA-β2 (1:1,000 rabbit polyclonal; AB5561; Millipore Sigma), GABAA-β3 (1:1,000 mouse monoclonal; ab98968; Abcam, Cambridge, UK), or β-actin (1:2,000 mouse monoclonal; A5441; Sigma-Aldrich) overnight at 4°C. Blots were washed with TBST and incubated in species-appropriate secondary antibodies (1:2,000) for 2 h at room temperature. Proteins were detected by chemiluminescence using a Supersignal West Femto Maximum Sensitivity kit (Thermo Scientific, Waltham, MA) and imaged with a G-Box (Syngene, Frederick, MD). Membranes were then washed in TBST and stripped with Restore PLUS stripping buffer (Thermo Scientific) before being reprobed. Separate blots were used for analysis of KCC2 and GABAA β-subunit protein expression. Densitometry was analyzed using ImageJ, and quantification of protein was normalized to β-actin.
Statistics.
Data from loose-patch recordings were analyzed for group- and time-dependent effects using two-way repeated-measures ANOVA or three-way ANOVA followed by Holm-Sidak post hoc tests. Mann-Whitney U-test were used to make baseline and area under the curve comparisons. Western blot and qRT-PCR data were analyzed by one-way ANOVA and Bonferroni t-tests. Analyses were performed using SigmaPlot software (v. 12.0; Systat Software, San Jose, CA).
RESULTS
AT1a KD results in reduced AT1a message compared with control.
To confirm the efficacy of AT1a KD to reduce AT1a mRNA, qRT-PCR was used to measure AT1a mRNA in MnPO punches from AT1a KD and Scr shRNA-injected rats. Message from AT1a KD rats was 33% reduced compared with control rats using 2-∆∆Ct analysis (Fig. 1B). One-way ANOVA shows that there was a significant effect of treatment [F(2,17) = 17.46, P < 0.001]. The AT1a KD was effective at reducing AT1a mRNA compared with samples from uninjected control rats (P < 0.001) and Scr-treated rats (P < 0.001). Control and Scr AT1a mRNA were not different from each other (P = 0.54).
AT1a KD impairs ANG II-dependent excitability in MnPO neurons.
The activity of MnPO neurons was monitored using in vitro loose-patch recordings to assess the effect of ANG II on spontaneous action potential firing in slices prepared from rats injected with either Scr or AT1a KD (Fig. 2, A–C). Neurons from rats that received Scr injections exhibited a mean basal firing rate of 1.4 ± 0.3 Hz (n = 12 cells from 6 rats). In contrast, neurons from rats that received the AT1a KD showed a higher basal firing rate (2.6 ± 0.6 Hz, n = 12 cells from 3 rats) compared with that observed in the Scr-injected rats (Fig. 2D). Mann-Whitney U-test showed that the basal firing rate of AT1a KD neurons was significantly higher than Scr neurons (P < 0.05, Fig. 2E).
Fig. 2.
Angiotensin responses in median preoptic nucleus (MnPO) neurons. A: representative raw loose-patch recordings of the effects of focally applied angiotensin II (ANG II) (100 nM, shaded bars) on the activity of green fluorescent protein (GFP)-labeled MnPO neurons in slices from scrambled sequence (Scr)-injected rats (left) and angiotensin type 1a knockdown (AT1a KD)-injected rats (right). B and C: firing rate histograms of the recordings in A showing that ANG II (shaded bar) increases spontaneous activity of Scr-injected (B) but not AT1a KD (C) MnPO neurons. D: summary of firing rate data shows that ANG II-mediated increases in activity seen in Scr (n = 12) MnPO neurons are blocked by bath application of losartan (10 µM, n = 12) and AT1a KD (n = 12). E: AT1a KD is associated with an increase in baseline spontaneous activity. F: summary data showing that ANG II application had no significant effect on the activity of neurons from AT1a KD rats but induced a significant threefold increase from baseline in spontaneous activity in neurons from Scr rats. Losartan blocked the ANG II-mediated increase in activity in neurons from Scr rats. G: integrated area in response to ANG II was significantly greater in Scr compared with AT1a KD and Scr + Losartan. *P < 0.05. AUC, area under the curve.
In Scr neurons, focal application of ANG II resulted in a transient increase in firing rate (9 of 12 neurons) that peaked within 2 min and persisted for 10 min. Bath application of the AT1a antagonist losartan did not significantly alter the basal firing rate of MnPO neurons in vitro (1.5 ± 0.2 Hz, n = 12 cells from 3 rats), but losartan did block the responses to ANG II (Fig. 2F). In rats that received the AT1a KD, ANG II failed to produce a change in firing rate (Fig. 2F). Two-way repeated-measures ANOVA on normalized firing rate shows that there was a significant effect of treatment [F(2,33) = 4.00, P < 0.05)] time [F(19,627) = 3.16, P < 0.001], and an interaction between treatment and time [F(38,627) = 1.44, P < 0.05] following application of ANG II. Holm-Sidak post hoc test shows that firing rate of AT1a KD neurons was significantly reduced in response to ANG II application compared with Scr neurons (P < 0.05). The percentage change in firing rate of AT1a KD neurons was smaller than Scr neurons 2 min following ANG II application and was no different from baseline activity. The integrated area of the ANG II response was calculated as the magnitude of the change in firing rate compared with the mean basal firing over the 10-min period following ANG II application (Fig. 2G). The greatest average integrated area was observed in the Scr group and was significantly larger than the AT1a KD group and the Scr + losartan group (Mann-Whitney U-test, P < 0.05). There was no significant difference between the AT1a KD group and the Scr + losartan group.
GABAA-mediated inhibition is impaired in AT1a KD in loose-patch recordings.
To assess the effects of AT1a KD on GABAA receptor function, we applied muscimol (100 µM) to the slices for 30 s using a Pico spritzer. The baseline firing rates for MnPO neurons in these experiments were as follows: Scr 0.94 ± 0.21 Hz (n = 10 cells from 3 rats), AT1a KD 1.79 ± 0.53 Hz (n = 10 cells from 3 rats), and unlabeled 1.78 ± 0.36 Hz (n = 11 cells from 3 rats). MnPO neurons injected with the Scr exhibited a pronounced reduction in spontaneous action potential firing upon application of muscimol (Fig. 3, A and B). The muscimol-dependent reduction in spontaneous activity persisted for 9 min following termination of muscimol application. Unlabeled MnPO neurons (i.e., those that did not express GFP and hence did not express the shRNA) also showed a robust inhibition in response to muscimol that persisted for the 10-min duration of the recording. The magnitude and time course of the muscimol effect were not significantly different between Scr (n = 10 cells from 3 rats) and unlabeled (n = 11 cells from 3 rats) MnPO neurons (Fig. 3C). Muscimol did not alter firing rate of labeled cells from slices prepared from rats injected with AT1a KD compared with their baseline firing. Two-way repeated-measures ANOVA of normalized firing rates showed that, although there was no significant effect of treatment [F(2,28) = 1.82, P = 0.18], there was a time-dependent effect [F(19,532) = 5.85, P < 0.001] and an interaction between treatment and time [F(38,532) = 1.50, P < 0.05]. AT1a KD did reduce the initial inhibitory effect of muscimol during the first 1.5 min following application compared with Scr or unlabeled controls (Holm-Sidak post hoc tests, both P < 0.01). Furthermore, bath application of the GABAA antagonist bicuculline (10 µM) significantly increased basal activity in Scr (paired t-test, P < 0.01, n = 13 cells from 3 rats) but did not alter basal activity in AT1a KD (paired t-test, P = 0.67, n = 9 cells from 3 rats). This indicates that AT1a KD significantly attenuated the inhibitory effects of GABAA receptor activation.
Fig. 3.
Effects of angiotensin type 1a knockdown (AT1a KD) on muscimol-mediated inhibition. AT1a KD significantly reduced the inhibitory effects of focal applications of muscimol (100 µM, shaded bar) on the firing rate (A) and percentage of baseline (B) of median preoptic nucleus (MnPO) neurons from AT1a KD-injected rats (n = 10) compared with neuron from slices from scrambled sequence (Scr)-injected rats (n = 10) and unlabeled control (n = 11). C: data from B expressed as integrated area under the curve (AUC). D: bicuculline increases basal firing in Scr neurons (n = 13) but not AT1a KD neurons (n = 9). *P < 0.05, **P < 0.01.
KCC2 and AT1a interaction.
Because we observed reduced GABAA-mediated inhibition associated with AT1a KD, we tested for changes in expression of GABAA receptor subunits by qRT-PCR and Western blot analysis (Fig. 4A). We used qRT-PCR to compare the expression in β-subunit mRNA for the GABAA receptor in AT1a KD to Scr-injected rats. We failed to detect a difference in β-subunit mRNA between AT1a KD and Scr rats for all three subunits (β1 P = 0.71, β2 P = 0.12, β3 P = 0.62). We also investigated whether there was reduction in GABAA β-subunit protein expression despite the failure to detect a significant AT1a KD-mediated reduction in β-subunit mRNA (Fig. 4, B and C). We failed to detect expression of the β1-subunit and failed to detect differences in β3-subunit protein expression between MnPO samples from AT1a KD- and Scr-treated rats. There was a trend toward a reduction in β2-subunit expression in the AT1a KD compared with Scr, but this was not significant (P = 0.07).
Fig. 4.
Angiotensin type 1a knockdown (AT1a KD) had no effect on γ-aminobutyric acid (GABA)A β-subunit expression. A: AT1a KD (n = 7) was not associated with a significant reduction in β-subunit mRNA for GABAA receptors compared with scrambled sequence (Scr) (n = 7). B: similarly, AT1a KD (n = 3) was not associated with a significant reduction in β-subunit protein for GABAA receptors compared with Scr (n = 3). C: Western blots for the β-subunit expression with β-actin loading controls.
Because we failed to detect decreases in GABAA β-subunit mRNA and protein expression associated with AT1a KD, we tested for changes in chloride transporter expression to determine whether changes in the Cl− gradient might underlie the impaired GABAA-mediated inhibition in the AT1a KD (Fig. 5A). Analysis of KCC2 mRNA expression showed that AT1a KD resulted in a reduction in KCC2 mRNA compared with the Scr (P = 0.034).
Fig. 5.
Angiotensin type 1a knockdown (AT1a KD) reduced KCC2 mRNA and S940 phosphorylation in the median preoptic nucleus (MnPO). A: KCC2 mRNA was reduced in AT1a KD (n = 7) compared with scrambled sequence (Scr) (n = 7). B: there was no difference in total KCC2 protein between AT1a KD (n = 3) and Scr (n = 4). C: there was a reduction in pS940 KCC2 in AT1a KD. D: there was a reduction in the ratio of pS940 KCC2/total KCC2 compared with Scr. E: Western blots show expression of total KCC2 and pKCC2 in AT1a KD- and Scr-treated tissue. *P < 0.05.
We also investigated whether the reduction in KCC2 mRNA was accompanied by a reduction in KCC2 protein expression. The reduction in KCC2 mRNA was not associated with a reduction in total KCC2 protein expression (P = 0.54, Fig. 5B). However, AT1a KD was associated with a reduction in pS940 KCC2 protein (P = 0.013, Fig. 5C). The ratio of pKCC2/β-actin was reduced in AT1a KD rats (n = 4, Fig. 5D). The reduction in pS940 KCC2 observed in AT1a KD was significantly reduced [1-way ANOVA: F(1,5) = 14.210, P < 0.05] compared with Scr-injected rats (n = 3).
To further test the role of KCC2 in GABAA-mediated inhibition, we conducted electrophysiological experiments to determine the effects of pharmacological blockade of KCC2 on GABAA-mediated inhibition using loose-patch recording (Fig. 6A). As before, cells from AT1a KD rats demonstrated impaired GABAA-mediated inhibition compared with Scr (Holm-Sidak post hoc, P < 0.001). In cells from Scr rats, bath application of the KCC2 blocker VU 0240551 impaired GABAA-mediated inhibition compared with GABAA-mediated inhibition in aCSF (Holm-Sidak post hoc, P < 0.001). The impaired GABAA-mediated inhibition observed in cells from the AT1a KD rats was not reduced further in the presence of VU 0240551 (Holm-Sidak post hoc, P = 0.25). As before, there was a reduction in the magnitude of the integrated area in AT1a KD-treated rats compared with Scr. Bath application of the KCC2 blocker did not further reduce integrated area in AT1a KD rats but did reduce the magnitude of the integrated area in Scr rats (Fig. 6B). There was a trend toward blockade of KCC2 increasing the basal firing of Scr neurons (Fig. 6C) that did not reach significance (t-test, P = 0.06). Additionally, blockade of KCC2 did not alter the basal firing of AT1a KD neurons (t-test, P = 0.89). This suggests that the AT1a KD-mediated attenuation of GABAA-mediated inhibition involves an altered function of KCC2.
Fig. 6.
Effects of KCC2 blockade on muscimol inhibition in median preoptic nucleus (MnPO) neurons. A: γ-aminobutyric acid (GABA)A-mediated inhibition produced by muscimol (100 µM) seen in the scrambled sequence (Scr) (n = 9) MnPO neurons was reduced by KCC2 blockade with VU 0240551 (10 µM). The impaired GABAA-mediated inhibition seen in the angiotensin type 1a knockdown (AT1a KD) (n = 8) was not further reduced by bath application of a KCC2 blocker. B: integrated area under the curve (AUC) for percentage of baseline measures was reduced in all AT1a KD and in Scr MnPO neurons treated with a KCC2 blocker. *P < 0.05. C: KCC2 inhibition with VU 0240551 did not influence firing rate.
KCC2 has been shown to require phosphorylation of S940 to be stably expressed in the cell membrane, and phosphorylation of this residue is maintained by serine/threonine kinases via PKC and PLC. To further investigate the mechanisms linking AT1a to KCC2 function, we looked to see whether we could recover function of KCC2 and subsequently GABAA-mediated inhibition in AT1a KD (Fig. 7A) rats by directly activating PKC/PLC (downstream effectors of AT1a activation). There was a significant effect of drug application on GABAA-mediated inhibition [F(2,27) = 3.99, P < 0.05]. As shown before, the inhibitory effects of muscimol were reduced significantly in neurons from slices prepared from AT1a KD rats (Fig. 7A). Application of PDBu, a PKC activator, recovered GABAA-mediated inhibition in the AT1a KD (P < 0.05). Additionally, activation of PLC using m-3M3FBS recovered GABAA-mediated inhibition (P < 0.05) but was not different in recovering GABAA-mediated inhibition in AT1a KD from PDBu (P = 0.75). However, application of either PKC or PLC activators failed to alter GABAA-mediated inhibition in cells from Scr rats (Fig. 7B). The magnitude of integrated area was only reduced in MnPO neurons from AT1a KD rats treated with aCSF (Fig. 7C). Bath application of PKC or PLC activators did not alter the basal firing rate of AT1a KD or Scr neurons (data not shown).
Fig. 7.
Effects of pharmacological activation of phospholipase C (PLC) or protein kinase C (PKC) on muscimol-mediated inhibition of neurons from scrambled sequence (Scr)- and angiotensin type 1a knockdown (AT1a KD)-injected rats. A: impaired γ-aminobutyric acid (GABA)A-mediated inhibition in response to muscimol application (100 µM, shaded bar) was observed in AT1a KD median preoptic nucleus (MnPO) neurons (n = 10). Bath application of the PLC activator m-3M3FBS (10 µM; n = 8) or the PKC activator phorbol 12,13-dibutyrate (PDBu) (10 µM; n = 12) recovered GABAA-mediated inhibition in AT1a KD neurons in MnPO. B: GABAA-mediated inhibition seen in Scr MnPO neurons (n = 10) was not altered by bath application of PLC (n = 13) or PKC (n = 9) activators. C: integrated area under the curve (AUC) in response to muscimol application was not reduced in AT1a KD MnPO treated with a PLC or a PKC activator. *P < 0.05 compared with Scr treated with artificial cerebrospinal fluid (aCSF).
DISCUSSION
Focal application of ANG II increased the spontaneous firing in MnPO neurons consistent with previous reports demonstrating the excitatory effects of ANG II in the MnPO (1, 36). Virally mediated AT1a KD reduced mRNA expression for the receptor in the MnPO and blocked the excitatory effects of exogenous ANG II application. The AT1a KD was as effective at blocking the excitatory effects of ANG II as the AT1a antagonist losartan. However, AT1a KD was also associated with an increase in basal firing, whereas AT1a inhibition with losartan was not associated with an increase in basal firing. Although losartan did not alter spontaneous firing in MnPO neurons in the above loose-patch voltage-clamp recordings, it has been shown to reduce inhibitory currents in whole cell voltage-clamp recordings (16).
The AT1a KD-mediated increases in basal activity were due to reductions in GABAA-mediated inhibition. In the present experiment, the GABAA agonist muscimol induced a robust inhibition in spontaneous activity of Scr-injected MnPO neurons. In neurons from AT1a KD rats, muscimol-mediated inhibition was greatly reduced. However, this reduced response to muscimol associated with AT1a KD in the MnPO was not associated with significant reductions in GABAA β-subunit expression of mRNA or protein (although there was a trend toward a reduction in β2-subunit mRNA). This suggests that the effects of AT1a KD on GABAA responses do not involve a direct effect on the receptor.
We next tested for possible changes in Cl− homeostasis, as it has been shown that GPCR regulates the membrane expression of KCC2 (29). Inhibition of KCC2, a K+/Cl− cotransporter involved in maintaining low intracellular Cl− concentrations, reduced the inhibitory effects of GABAA receptor activation in cells recorded in slices from rats injected with the control vector. In slices from rats treated with shRNA against AT1a, KCC2 inhibition did not influence GABAA-mediated inhibition, suggesting that the KCC2 activity was already compromised. This finding is consistent with a change in KCC2 expression and/or function associated with AT1a KD. As shown above, AT1a KD was associated with a reduction in KCC2 mRNA, and reductions in transcription have been shown to reduce GABAA currents (21). Reductions in mRNA do not necessarily translate to reductions in functional protein. In fact, AT1a KD did not reduce total KCC2 protein expression in the MnPO. However, there was a reduction in S940 phosphorylation of KCC2 in the MnPO of AT1a KD-treated rats. Phosphorylation of KCC2, specifically at S940, has been shown to be important for stabilizing membrane expression of KCC2, and it is PKC dependent (25, 26). Although it has not been demonstrated that PLC directly interacts with KCC2 to modify phosphorylation, PLC does upregulate diacylglycerol- and inositol triphosphate-dependent increases in intracellular calcium, both of which increase the activity of PKC. Other GPCR systems have been shown to modulate KCC2 function. Activation of group 1 mGluRs, a receptor system that upregulates PKC function, has been shown to mediate GABA inhibition through the regulation of KCC2 (3). The present study suggests that chronic inhibition of AT1a function is associated with reduced GABAA inhibition through a decrease in KCC2 function.
Activation of AT1a receptors increases PLC and PKC activity (5). Bath application of PLC and PKC activators was effective in recovering GABAA-mediated inhibition of spontaneous activity in cells transfected with shRNA against AT1a. Although PLC/PKC activation in Src controls did not enhance GABAA-mediated inhibition of spontaneous activity, it is still possible that there was an increase in the magnitude of inhibitory currents. The recording methods in these experiments were limited to measurements of firing rate and, therefore, subject to floor effects. Another possibility is that constitutive activity of PLC/PKC pathway is high enough that phosphorylation of KCC2 cannot be increased further.
The above experiments implicate a role for AT1a receptors in the modulation of GABAA-mediated inhibition. This permissive AT1a receptor effect appears to be mediated by PLC/PKC-dependent phosphorylation of KCC2. This suggests that angiotensin in the MnPO may play an important modulatory role that supports the inhibitory effects of GABA. Maintaining the inhibitory effects of GABA could be important in maintaining the balance between inhibition and excitation in this nucleus. Changes in the excitatory/inhibitory balance within MnPO neurons could influence body fluid homeostasis, central cardiovascular control, thermoregulation, and sleep homeostasis. Chronic intermittent hypoxia (CIH), an animal model simulating the hypoxemia associated with sleep apnea, is associated with a sustained increase in blood pressure that persists even during periods of normoxia (13, 22). Neuronal activity (as measured by FosB staining) in the MnPO is increased following CIH (22). Additionally, intracerebroventricular infusions of losartan block CIH-induced hypertension as well as increases in FosB staining (23). This suggests a role of AT1a receptor activation in the pathogenesis of CIH-induced hypertension. Further studies are required to determine the role of AT1a receptors in CIH-induced hypertension and whether that role involves AT1a-mediated changes in Cl− homeostasis.
It has been shown that the SFO utilizes ANG II as a neurotransmitter in its projections to the paraventricular nucleus (PVN) (2, 28) and may also utilize ANG II as a neurotransmitter in projections to the MnPO. ANG II-dependent activation of AT1a receptors in the PVN has been shown to be excitatory (8, 27). Activation of preautonomic PVN neurons via AT1a receptor stimulation can thus enhance blood pressure through projections to the rostral ventrolateral medulla (10, 35). In much the same way, ANG II-mediated activation of MnPO could influence blood pressure through projections to the PVN (15, 19, 39).
The central effects of ANG II on blood pressure are not static and can exhibit plasticity. Chronic peripheral administration of a nonpressor dose of ANG II has been shown to sensitize subsequent pressor doses of ANG II and enhance hypertension through central ANG II receptors (42). The induction of this sensitization to ANG II has also been demonstrated with chronic administration of aldosterone (43) or a high-salt diet (9). Although acute exposure to elevated levels of ANG II can enhance neuronal excitability and transiently increase blood pressure, chronic elevations may sensitize the neuronal responses to ANG II.
The results from the present study suggest that the AT1a receptor contributes to two seemingly opposing effects in MnPO neurons. The excitatory effects of ANG II lead to increased activity and appear to occur on an acute time scale. In contrast, constitutive activity of the AT1a may be necessary for the inhibitory effects of GABA. The net effect of AT1a receptors in MnPO neurons may be to contribute to synaptic homeostasis or maintain a balance between inhibition and excitation, needed for the MnPO to play its role in several different organismal homeostatic systems. Changes in angiotensin signaling could alter synaptic homeostasis in the MnPO, which could have functional consequences for behavioral and physiological systems that are regulated by this region. Different patterns of ANG II administration can produce desensitization (12) or sensitization (17, 20) of AT1a-mediated responses, and these changes in sensitivity may involve different signaling pathways (20, 41). The functional consequences of desensitization or sensitization of AT1a receptors in MnPO could depend on how these different electrophysiological responses are integrated to influence the activity of downstream targets.
Perspectives and Significance
The present study demonstrates a novel interaction between AT1a receptors and GABAA inhibition in MnPO neurons. Chronic AT1a receptor knockdown appears to decrease GABAA inhibition not through changes in GABAA receptor efficacy but rather through the regulation of the K+/Cl− cotransport system. Here, loss of AT1a receptor function disrupts the chloride homeostasis and reduces GABAA-mediated inhibition. It has been previously shown that acute pharmacological inhibition of AT1 receptors can influence GABAA receptors without influencing chloride transport although this affect appeared to be limited to sodium-sensitive cells (16). It could be that chronic vs. acute inhibition of AT1a may involve different mechanisms that regulate GABAA inhibition.
The MnPO is involved in body fluid homeostasis and cardiovascular control as well as thermoregulation and sleep (30). The interaction between AT1a and GABAA receptors may be involved in maintaining synaptic homeostasis through control of the excitatory/inhibitory balance of MnPO neurons. Changes in this excitatory/inhibitory balance could impair the regulatory function of the MnPO. For example, dysregulation of excitatory/inhibitory balance in MnPO neurons may occur at physiological or pathophysiological states featuring AT1a overactivation. Although the present study did not address the effects of AT1a overactivation, as might be observed in hypertension, future studies would benefit from such investigations of the role of elevated AT1a activation on GABAA-mediated inhibition.
GRANTS
This work was supported by National Heart, Lung, and Blood Institute Grant P01-HL-088052.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the authors.
AUTHOR CONTRIBUTIONS
G.E.F. and J.T.C. conceived and designed research; G.E.F., K.B., M.E.B., and J.T.L. performed experiments; G.E.F., K.B., M.E.B., and J.T.L. analyzed data; G.E.F., K.B., M.E.B., J.T.L., and J.T.C. interpreted results of experiments; G.E.F., K.B., and J.T.C. prepared figures; G.E.F. and J.T.C. drafted manuscript; G.E.F. and J.T.C. edited and revised manuscript; G.E.F., K.B., and J.T.C. approved final version of manuscript.
ACKNOWLEDGMENTS
We thank Alexandria Marciante and Anna Amune for technical assistance.
REFERENCES
- 1.Bai D, Renaud LP. ANG II AT1 receptors induce depolarization and inward current in rat median preoptic neurons in vitro. Am J Physiol Regul Integr Comp Physiol 275: R632–R639, 1998. [DOI] [PubMed] [Google Scholar]
- 2.Bains JS, Potyok A, Ferguson AV. Angiotensin II actions in paraventricular nucleus: functional evidence for neurotransmitter role in efferents originating in subfornical organ. Brain Res 599: 223–229, 1992. doi: 10.1016/0006-8993(92)90395-P. [DOI] [PubMed] [Google Scholar]
- 3.Banke TG, Gegelashvili G. Tonic activation of group I mGluRs modulates inhibitory synaptic strength by regulating KCC2 activity. J Physiol 586: 4925–4934, 2008. doi: 10.1113/jphysiol.2008.157024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Brody MJ, Fink GD, Buggy J, Haywood JR, Gordon FJ, Johnson AK. The role of the anteroventral third ventricle (AV3V) region in experimental hypertension. Circ Res 43: I2–I13, 1978. https://www.researchgate.net/publication/279934674_The_role_of_the_anteroventral_third_ventral_AV3V_region_in_experimental_hypertension. [DOI] [PubMed] [Google Scholar]
- 5.Capponi AM. Distribution and signal transduction of angiotensin II AT1 and AT2 receptors. Blood Press Suppl 2: 41–46, 1996. [PubMed] [Google Scholar]
- 7.Carreño FR, Walch JD, Dutta M, Nedungadi TP, Cunningham JT. Brain-derived neurotrophic factor-tyrosine kinase B pathway mediates NMDA receptor NR2B subunit phosphorylation in the supraoptic nuclei following progressive dehydration. J Neuroendocrinol 23: 894–905, 2011. doi: 10.1111/j.1365-2826.2011.02209.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Cato MJ, Toney GM. Angiotensin II excites paraventricular nucleus neurons that innervate the rostral ventrolateral medulla: an in vitro patch-clamp study in brain slices. J Neurophysiol 93: 403–413, 2005. doi: 10.1152/jn.01055.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Clayton SC, Zhang Z, Beltz T, Xue B, Johnson AK. CNS neuroplasticity and salt-sensitive hypertension induced by prior treatment with subpressor doses of ANG II or aldosterone. Am J Physiol Regul Integr Comp Physiol 306: R908–R917, 2014. doi: 10.1152/ajpregu.00010.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Coote JH, Yang Z, Pyner S, Deering J. Control of sympathetic outflows by the hypothalamic paraventricular nucleus. Clin Exp Pharmacol Physiol 25: 461–463, 1998. doi: 10.1111/j.1440-1681.1998.tb02235.x. [DOI] [PubMed] [Google Scholar]
- 11.Cunningham JT, Nedungadi TP, Walch JD, Nestler EJ, Gottlieb HB. ΔFosB in the supraoptic nucleus contributes to hyponatremia in rats with cirrhosis. Am J Physiol Regul Integr Comp Physiol 303: R177–R185, 2012. doi: 10.1152/ajpregu.00142.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Daniels D. Angiotensin II (de)sensitization: fluid intake studies with implications for cardiovascular control. Physiol Behav 162: 141–146, 2016. doi: 10.1016/j.physbeh.2016.01.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Fletcher EC. Invited review. Physiological consequences of intermittent hypoxia: systemic blood pressure. J Appl Physiol (1985) 90: 1600–1605, 2001. doi: 10.1152/jappl.2001.90.4.1600. [DOI] [PubMed] [Google Scholar]
- 14.Grobe JL, Xu D, Sigmund CD. An intracellular renin-angiotensin system in neurons: fact, hypothesis, or fantasy. Physiology (Bethesda) 23: 187–193, 2008. doi: 10.1152/physiol.00002.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Gu GB, Simerly RB. Projections of the sexually dimorphic anteroventral periventricular nucleus in the female rat. J Comp Neurol 384: 142–164, 1997. doi:. [DOI] [PubMed] [Google Scholar]
- 16.Henry M, Grob M, Mouginot D. Endogenous angiotensin II facilitates GABAergic neurotransmission afferent to the Na+-responsive neurons of the rat median preoptic nucleus. Am J Physiol Regul Integr Comp Physiol 297: R783–R792, 2009. doi: 10.1152/ajpregu.00226.2009. [DOI] [PubMed] [Google Scholar]
- 17.Hurley SW, Zhang Z, Beltz TG, Xue B, Johnson AK. Sensitization of sodium appetite: evidence for sustained molecular changes in the lamina terminalis. Am J Physiol Regul Integr Comp Physiol 307: R1405–R1412, 2014. doi: 10.1152/ajpregu.00210.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Johnson AK, Cunningham JT, Thunhorst RL. Integrative role of the lamina terminalis in the regulation of cardiovascular and body fluid homeostasis. Clin Exp Pharmacol Physiol 23: 183–191, 1996. doi: 10.1111/j.1440-1681.1996.tb02594.x. [DOI] [PubMed] [Google Scholar]
- 19.Johnson AK, Zardetto-Smith AM, Edwards GL. Integrative mechanisms and the maintenance of cardiovascular and body fluid homeostasis: the central processing of sensory input derived from the circumventricular organs of the lamina terminalis. Prog Brain Res 91: 381–393, 1992. doi: 10.1016/S0079-6123(08)62357-2. [DOI] [PubMed] [Google Scholar]
- 20.Johnson AK, Zhang Z, Clayton SC, Beltz TG, Hurley SW, Thunhorst RL, Xue B. The roles of sensitization and neuroplasticity in the long-term regulation of blood pressure and hypertension. Am J Physiol Regul Integr Comp Physiol 309: R1309–R1325, 2015. doi: 10.1152/ajpregu.00037.2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Karadsheh MF, Delpire E. Neuronal restrictive silencing element is found in the KCC2 gene: molecular basis for KCC2-specific expression in neurons. J Neurophysiol 85: 995–997, 2001. doi: 10.1152/jn.2001.85.2.995. [DOI] [PubMed] [Google Scholar]
- 22.Knight WD, Little JT, Carreno FR, Toney GM, Mifflin SW, Cunningham JT. Chronic intermittent hypoxia increases blood pressure and expression of FosB/ΔFosB in central autonomic regions. Am J Physiol Regul Integr Comp Physiol 301: R131–R139, 2011. doi: 10.1152/ajpregu.00830.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Knight WD, Saxena A, Shell B, Nedungadi TP, Mifflin SW, Cunningham JT. Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia. Am J Physiol Regul Integr Comp Physiol 305: R1051–R1058, 2013. doi: 10.1152/ajpregu.00541.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Kolaj M, Bai D, Renaud LP. GABAB receptor modulation of rapid inhibitory and excitatory neurotransmission from subfornical organ and other afferents to median preoptic nucleus neurons. J Neurophysiol 92: 111–122, 2004. doi: 10.1152/jn.00014.2004. [DOI] [PubMed] [Google Scholar]
- 25.Lee HH, Deeb TZ, Walker JA, Davies PA, Moss SJ. NMDA receptor activity downregulates KCC2 resulting in depolarizing GABAA receptor-mediated currents. Nat Neurosci 14: 736–743, 2011. doi: 10.1038/nn.2806. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Lee HH, Walker JA, Williams JR, Goodier RJ, Payne JA, Moss SJ. Direct protein kinase C-dependent phosphorylation regulates the cell surface stability and activity of the potassium chloride cotransporter KCC2. J Biol Chem 282: 29777–29784, 2007. doi: 10.1074/jbc.M705053200. [DOI] [PubMed] [Google Scholar]
- 27.Li DP, Pan HL. Angiotensin II attenuates synaptic GABA release and excites paraventricular-rostral ventrolateral medulla output neurons. J Pharmacol Exp Ther 313: 1035–1045, 2005. doi: 10.1124/jpet.104.082495. [DOI] [PubMed] [Google Scholar]
- 28.Li Z, Ferguson AV. Subfornical organ efferents to paraventricular nucleus utilize angiotensin as a neurotransmitter. Am J Physiol Regul Comp Physiol 265: R302–R309, 1993. doi: 10.1152/ajpregu.1993.265.2.R302. [DOI] [PubMed] [Google Scholar]
- 29.Mahadevan V, Woodin MA. Regulation of neuronal chloride homeostasis by neuromodulators. J Physiol 594: 2593–2605, 2016. doi: 10.1113/JP271593. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.McKinley MJ, Yao ST, Uschakov A, McAllen RM, Rundgren M, Martelli D. The median preoptic nucleus: front and centre for the regulation of body fluid, sodium, temperature, sleep and cardiovascular homeostasis. Acta Physiol (Oxf) 214: 8–32, 2015. doi: 10.1111/apha.12487. [DOI] [PubMed] [Google Scholar]
- 31.Nedungadi TP, Cunningham JT. Differential regulation of TRPC4 in the vasopressin magnocellular system by water deprivation and hepatic cirrhosis in the rat. Am J Physiol Regul Integr Comp Physiol 306: R304–R314, 2014. doi: 10.1152/ajpregu.00388.2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Nedungadi TP, Dutta M, Bathina CS, Caterina MJ, Cunningham JT. Expression and distribution of TRPV2 in rat brain. Exp Neurol 237: 223–237, 2012. doi: 10.1016/j.expneurol.2012.06.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. New York, NY: Academic, 1986. [Google Scholar]
- 34.Saxena A, Little JT, Nedungadi TP, Cunningham JT. Angiotensin II type 1a receptors in subfornical organ contribute towards chronic intermittent hypoxia-associated sustained increase in mean arterial pressure. Am J Physiol Heart Circ Physiol 308: H435–H446, 2015. doi: 10.1152/ajpheart.00747.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Shafton AD, Ryan A, Badoer E. Neurons in the hypothalamic paraventricular nucleus send collaterals to the spinal cord and to the rostral ventrolateral medulla in the rat. Brain Res 801: 239–243, 1998. doi: 10.1016/S0006-8993(98)00587-3. [DOI] [PubMed] [Google Scholar]
- 36.Spanswick D, Renaud LP. Angiotensin II induces calcium-dependent rhythmic activity in a subpopulation of rat hypothalamic median preoptic nucleus neurons. J Neurophysiol 93: 1970–1976, 2005. doi: 10.1152/jn.00769.2004. [DOI] [PubMed] [Google Scholar]
- 37.Tanaka J, Nomura M. Involvement of neurons sensitive to angiotensin II in the median preoptic nucleus in the drinking response induced by angiotensin II activation of the subfornical organ in rats. Exp Neurol 119: 235–239, 1993. doi: 10.1006/exnr.1993.1025. [DOI] [PubMed] [Google Scholar]
- 38.Tanaka J, Saito H, Kaba H. Subfornical organ and hypothalamic paraventricular nucleus connections with median preoptic nucleus neurons: an electrophysiological study in the rat. Exp Brain Res 68: 579–585, 1987. doi: 10.1007/BF00249800. [DOI] [PubMed] [Google Scholar]
- 39.Thompson RH, Swanson LW. Structural characterization of a hypothalamic visceromotor pattern generator network. Brain Res Brain Res Rev 41: 153–202, 2003. doi: 10.1016/S0165-0173(02)00232-1. [DOI] [PubMed] [Google Scholar]
- 40.van Thiel BS, Góes Martini A, Te Riet L, Severs D, Uijl E, Garrelds IM, Leijten FPJ, van der Pluijm I, Essers J, Qadri F, Alenina N, Bader M, Paulis L, Rajkovicova R, Domenig O, Poglitsch M, Danser AHJ. Brain renin-angiotensin system: does it exist? Hypertension 69: 1136–1144, 2017. doi: 10.1161/HYPERTENSIONAHA.116.08922. [DOI] [PubMed] [Google Scholar]
- 41.Vento PJ, Daniels D. Mitogen-activated protein kinase is required for the behavioural desensitization that occurs after repeated injections of angiotensin II. Exp Physiol 97: 1305–1314, 2012. doi: 10.1113/expphysiol.2012.065771. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Xue B, Zhang Z, Johnson RF, Johnson AK. Sensitization of slow pressor angiotensin II (Ang II)-initiated hypertension: induction of sensitization by prior Ang II treatment. Hypertension 59: 459–466, 2012. doi: 10.1161/HYPERTENSIONAHA.111.185116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Xue B, Zhang Z, Roncari CF, Guo F, Johnson AK. Aldosterone acting through the central nervous system sensitizes angiotensin II-induced hypertension. Hypertension 60: 1023–1030, 2012. doi: 10.1161/HYPERTENSIONAHA.112.196576. [DOI] [PMC free article] [PubMed] [Google Scholar]